We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$106B
AUM Growth
+$2.27B
Cap. Flow
-$488M
Cap. Flow %
-0.46%
Top 10 Hldgs %
30.07%
Holding
4,478
New
179
Increased
2,056
Reduced
1,848
Closed
61

Top Buys

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$101M
2
GEV icon
GE Vernova
GEV
+$75.4M
3
CRH icon
CRH
CRH
+$48.5M
4
CRWD icon
CrowdStrike
CRWD
+$45.8M
5
DELL icon
Dell
DELL
+$35.8M

Sector Composition

Rank Sector Weight
1 Technology 30.98%
2 Financials 12.55%
3 Healthcare 11.48%
4 Consumer Discretionary 10.52%
5 Industrials 8.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JFIN
3501
Jiayin Group
JFIN
$137M
$17K ﹤0.01%
2,720
+70
+3% +$459
NKLA
3502
DELISTED
Nikola Corporation Common Stock
NKLA
$16.7K ﹤0.01%
2,043
-32,040
-94% -$572K
KZR
3503
DELISTED
Kezar Life Sciences
KZR
$16.5K ﹤0.01%
2,755
-8,189
-75% -$62.2K
DAVA icon
3504
Endava
DAVA
$155M
$16.5K ﹤0.01%
563
+105
+23% +$3.12K
MTLS
3505
Materialise
MTLS
$397M
$16.4K ﹤0.01%
3,283
+30
+0.9% +$154
MTL.PR
3506
DELISTED
Mechel PAO American Depositary Shares (each representing one-half of a Preferred Share)
MTL.PR
$16.4K ﹤0.01%
13,618
ADAP
3507
DELISTED
Adaptimmune Therapeutics
ADAP
$16.3K ﹤0.01%
16,721
+9,599
+135% +$10.5K
CUTR
3508
DELISTED
Cutera, Inc.
CUTR
$16.1K ﹤0.01%
10,676
-36,851
-78% -$74.1K
PAY icon
3509
Paymentus
PAY
$4.85B
$16K ﹤0.01%
844
-129
-13% -$2.53K
SVRE
3510
SaverOne 2014 Ltd
SVRE
$6.15M
$15.9K ﹤0.01%
5
+1
+25% +$5.56K
LPSN icon
3511
LivePerson
LPSN
$28.7M
$15.7K ﹤0.01%
1,796
-4,591
-72% -$44.1K
GRTS
3512
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$15.6K ﹤0.01%
25,183
-102,240
-80% -$86.4K
NIU
3513
Niu Technologies
NIU
$197M
$15.5K ﹤0.01%
8,884
-1,558
-15% -$3.2K
ENZL icon
3514
iShares MSCI New Zealand ETF
ENZL
$82.9M
$15.3K ﹤0.01%
337
TUYA
3515
Tuya Inc
TUYA
$1.07B
$15.3K ﹤0.01%
8,925
BIRD icon
3516
Smartbird Inc
BIRD
$21.5M
$15.2K ﹤0.01%
1,521
-5,864
-79% -$71.6K
VGAS icon
3517
Verde Clean Fuels
VGAS
$28.7M
$14.8K ﹤0.01%
3,572
-657
-16% -$2.97K
BTAI icon
3518
BioXcel Therapeutics
BTAI
$27.9M
$14.7K ﹤0.01%
719
-1,136
-61% -$38K
BLRX
3519
BioLineRX
BLRX
$12.1M
$14.6K ﹤0.01%
644
+186
+41% +$4.99K
CNTB
3520
Connect Biopharma Holdings
CNTB
$139M
$14.4K ﹤0.01%
9,500
-7,020
-42% -$11.5K
TEN
3521
Tsakos Energy Navigation Ltd
TEN
$1.17B
$14.3K ﹤0.01%
488
+233
+91% +$6.54K
TVGN icon
3522
Tevogen Inc. Common Stock
TVGN
$26.4M
$14.3K ﹤0.01%
+395
New +$25.7K
CFFI icon
3523
C&F Financial
CFFI
$281M
$14.3K ﹤0.01%
296
-3,346
-92% -$146K
KPTI icon
3524
Karyopharm Therapeutics
KPTI
$46.5M
$14.3K ﹤0.01%
1,095
-8,507
-89% -$141K
CCRD
3525
DELISTED
CoreCard
CCRD
$14.2K ﹤0.01%
976
-6,117
-86% -$80.5K

Similar funds

RhumbLine Advisers's Q2 2024 Portfolio in Review

As of Q2 2024, RhumbLine Advisers held 4,478 positions worth $106B, up 2.2% from $104B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

RhumbLine Advisers's Q2 2024 filing shows 179 new, 2,056 increased, 1,848 reduced and 61 closed positions. Its largest new stake was GE Vernova: 475,685 shares worth $81.6M. The largest sale was iShares Russell 1000 ETF, an estimated $180M.

By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q2 2024 buy was GE Vernova: 475,685 shares worth $81.6M.
  • RhumbLine Advisers added most to ExxonMobil in Q2 2024, an estimated $101M increase.
  • RhumbLine Advisers's biggest Q2 2024 reduction was iShares Russell 1000 ETF, cutting an estimated $180M.
  • RhumbLine Advisers fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $121M.
  • RhumbLine Advisers's ten largest holdings make up 30% of its $106B portfolio in Q2 2024.
  • RhumbLine Advisers opened 179 new positions and closed 61 in Q2 2024.
  • RhumbLine Advisers's portfolio value rose 2.2% quarter-over-quarter to $106B.

Based on RhumbLine Advisers's 13F filing for Q2 2024, filed 1 Aug 2024.